The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns
-
Published:2024-03
Issue:1
Volume:151
Page:103243
-
ISSN:0151-9638
-
Container-title:Annales de Dermatologie et de Vénéréologie
-
language:en
-
Short-container-title:Annales de Dermatologie et de Vénéréologie
Author:
Amini-Adle M., Arnault J.-P., Aubin F., Beneton N., Bens G., Brunet-Possenti F., Célerier P., Charles J., Crumbach L., Dalac S., Darras S., De Quatrebarbes J., Dinulescu M., Dutriaux C., Gaudy C., Gérard E., Giacchero D., Granel-Brocard F., Grange F., Jouary T.ORCID, Kramkimel N., Lebbé C., Le Corre Y., Legoupil D., Lesage C.ORCID, Lesimple T., Lorphelin J.-M., Mansard S., Martin L., Mary-Prey S.ORCID, Maubec E., Meyer N., Mignard C.ORCID, Montaudie H., Mortier L., Nardin C.ORCID, Neidhardt Berard E.-M., Pagès Laurent C., Peuvrel L.ORCID, Quereux Gaelle, Robert Caroline, Saiag Philippe, Saint-Jean Mélanie, Samimi M., Sassolas B., Scalbert C., Skowron F.ORCID, Steff M., Stoebner P.-E., Trablesi S., Visseaux L., Zehou O., Boespflug A.
|
|